ZIM
SRPT icon

Zacks Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Zacks Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,410
Closed -$579K – 615
2017
Q4 		$579K Buy
+10,410
New +$551K 0.01% 463

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Zacks Investment Management's SRPT Position: Q1 2018 in Review

Zacks Investment Management sold out of Sarepta Therapeutics (SRPT) in Q1 2018, closing a stake of 10,410 shares — an estimated $579K sold.

Zacks Investment Management first reported a position in SRPT in Q4 2017 and held it in 1 quarter. The position peaked at $579K in Q4 2017. 269 funds tracked by Wall St. Rank hold SRPT as of Q1 2018.

  • Zacks Investment Management reported no remaining Sarepta Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Zacks Investment Management sold 10,410 Sarepta Therapeutics shares in Q1 2018, an estimated $579K.
  • Zacks Investment Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 1 quarter.
  • Zacks Investment Management's Sarepta Therapeutics position peaked at $579K in Q4 2017.
  • 269 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2018.

Based on Zacks Investment Management's 13F filing for Q1 2018, filed 14 May 2018.